Press release
Adrenocortical Carcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
Adrenocortical Carcinoma Clinical Trials
"Adrenocortical Carcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenocortical Carcinoma Market.
The Adrenocortical Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Adrenocortical Carcinoma Pipeline Report:
• Adrenocortical Carcinoma Companies across the globe are diligently working toward developing novel Adrenocortical Carcinoma treatment therapies with a considerable amount of success over the years.
• Adrenocortical Carcinoma companies working in the treatment market are Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, HRA Pharma, Genentech, Cytovation AS, Orphagen Pharmaceuticals and others, are developing therapies for the Adrenocortical Carcinoma treatment
• Emerging Adrenocortical Carcinoma therapies such as Ipilimumab, Relacorilant, LYSODREN (Mitotane), EO2401 + Nivolumab, CyPep-1, OR-449 and others are expected to have a significant impact on the Adrenocortical Carcinoma market in the coming years.
• In January 2023, Orphagen Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) has granted a rare pediatric disease designation (RPDD) to OR-449 for treating pediatric ACC.
Adrenocortical Carcinoma Overview
Adrenocortical carcinoma (ACC) is a rare and aggressive cancer originating in the cortex of the adrenal glands, which are responsible for producing vital hormones such as cortisol, aldosterone, and androgens. ACC accounts for approximately 0.02% of all cancers, with an incidence of 1-2 cases per million people annually. It can occur at any age, but peaks are observed in children under 5 and adults in their 40s-50s.
The presentation of ACC varies depending on whether the tumor is functional (hormone-secreting) or non-functional. Functional tumors often cause hormonal imbalances, leading to symptoms like Cushing's syndrome (weight gain, high blood pressure, and diabetes) or virilization (excess male hormone features in women). Non-functional tumors are often asymptomatic until they grow large, causing abdominal pain or a palpable mass.
Diagnosis involves imaging studies such as CT or MRI, hormonal evaluations, and biopsy in some cases. Surgical resection remains the primary treatment for localized ACC, while advanced cases may require adjuvant therapies like mitotane, chemotherapy, or radiation.
Given its high recurrence rate and poor prognosis, with a 5-year survival rate of 20-45% for advanced stages, early detection and advancements in targeted therapies are critical to improving outcomes for ACC patients.
Get a Free Sample PDF Report to know more about Adrenocortical Carcinoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Adrenocortical Carcinoma Route of Administration
Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Adrenocortical Carcinoma Molecule Type
Adrenocortical Carcinoma Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide
Adrenocortical Carcinoma Pipeline Therapeutics Assessment
• Adrenocortical Carcinoma Assessment by Product Type
• Adrenocortical Carcinoma By Stage and Product Type
• Adrenocortical Carcinoma Assessment by Route of Administration
• Adrenocortical Carcinoma By Stage and Route of Administration
• Adrenocortical Carcinoma Assessment by Molecule Type
• Adrenocortical Carcinoma by Stage and Molecule Type
DelveInsight's Adrenocortical Carcinoma Report covers around 5+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Adrenocortical Carcinoma product details are provided in the report. Download the Adrenocortical Carcinoma pipeline report to learn more about the emerging Adrenocortical Carcinoma therapies- https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Adrenocortical Carcinoma Pipeline Analysis:
The Adrenocortical Carcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
• Adrenocortical Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market.
Download Sample PDF Report to know more about Adrenocortical Carcinoma drugs and therapies- https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Adrenocortical Carcinoma Pipeline Drug Insight
• Coverage: Global
• Adrenocortical Carcinoma companies: Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, HRA Pharma, Genentech. Cytovation AS, Orphagen Pharmaceuticals and others.
• Adrenocortical Carcinoma therapies: Ipilimumab, Relacorilant, LYSODREN (Mitotane), EO2401 + Nivolumab, CyPep-1, OR-449 and others.
• Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma current marketed and Adrenocortical Carcinoma emerging therapies
• Adrenocortical Carcinoma Market Dynamics: Adrenocortical Carcinoma market drivers and Adrenocortical Carcinoma market barriers
Request for Sample PDF Report for Adrenocortical Carcinoma Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Adrenocortical Carcinoma Report Introduction
2. Adrenocortical Carcinoma Executive Summary
3. Adrenocortical Carcinoma Overview:
4. Adrenocortical Carcinoma- Analytical Perspective In-depth Commercial Assessment
5. Adrenocortical Carcinoma Pipeline Therapeutics
6. Adrenocortical Carcinoma Late Stage Products (Phase II/III)
7. Adrenocortical Carcinoma Mid Stage Products (Phase II)
8. Adrenocortical Carcinoma Early Stage Products (Phase I)
9. Adrenocortical Carcinoma Preclinical Stage Products
10. Adrenocortical Carcinoma Therapeutics Assessment
11. Adrenocortical Carcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Adrenocortical Carcinoma Companies
14. Adrenocortical Carcinoma Key Products
15. Adrenocortical Carcinoma Unmet Needs
16 . Adrenocortical Carcinoma Market Drivers and Barriers
17. Adrenocortical Carcinoma Future Perspectives and Conclusion
18. Adrenocortical Carcinoma Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Deep Vein Thrombosis Market: https://www.delveinsight.com/report-store/deep-vein-thrombosis-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-market
• Diabetic Nephropathy Market: https://www.delveinsight.com/report-store/diabetic-nephropathy-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Endometriosis Pain Market: https://www.delveinsight.com/report-store/endometriosis-pain-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Facioscapulohumeral Muscular Dystrophy Market: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Generalized Anxiety Disorder Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Generalized Pustular Psoriasis Market: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Healthcare Portfolio Management Services: https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Human Papillomavirus Positive Cancer Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Menorrhalgia Market: https://www.delveinsight.com/report-store/menorrhalgia-market
• Metachromatic Leukodystrophy Market Research Report: https://www.delveinsight.com/report-store/metachromatic-leukodystrophy-mld-market
• Metastatic Bone Pain Market: https://www.delveinsight.com/report-store/metastatic-bone-pain-market
• Myelofibrosis Market: https://www.delveinsight.com/report-store/myelofibrosis-mf-market
• Ncfb Market: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenocortical Carcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3774089 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Adrenocortical
Adrenocortical Hormones API Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Drugs Market Overview: Growth, Share, Value, Size, and …
The global Adrenocortical Carcinoma Drugs market is projected to reach approximately USD 0.85 billion by 2033, growing at a compound annual growth rate (CAGR) of around 7.2% from 2025 to 2033.
Adrenocortical Carcinoma Drugs Market Overview
The global Adrenocortical Carcinoma (ACC) drugs market is experiencing growth, driven by the increasing incidence of this rare endocrine malignancy and advancements in therapeutic approaches. ACC is characterized by aggressive tumor behavior and limited treatment options,…
Adrenocortical Hormones API Market Survey Detailed Analysis and Forecast 2024-20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion…
Adrenocortical Carcinoma Treatment: Challenges, Advances, and Market Dynamics
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer originating in the adrenal cortex, the outer layer of the adrenal glands. These glands, located above the kidneys, are responsible for producing hormones that regulate a variety of bodily functions, such as metabolism, blood pressure, and immune response. ACC is often diagnosed at an advanced stage due to its asymptomatic early course, and treatment options are limited. In this…
Adrenocortical Hormones API Market Research Explores Revenue Share Study Analysi …
Adrenocortical Hormones API Market is valued at US$ 2.24 Billion in 2023, and it is expected to reach US$ 3.55 Billion by 2031, with a CAGR of 6.04 % during the forecast period of 2024-2031.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs,…
Adrenocortical Hormones API Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Adrenocortical Hormones API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Adrenocortical Hormones APImarket by key players, product type, applications and regions,etc.
The main objective of this market research is to help the readers understand the structure of Adrenocortical Hormones APImarket, market definition, overview, industry opportunities…
